Tisagenlecleucel

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameTisagenlecleucel
Drug Alias NameTisagenlecleucel-TQ6C9WHR03OChimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/NovartisAnti-CD19-chimeric-antigen-receptor-retroviral-vector-transduced-autologous-T-cells-NovartisAnti-CD19-chimeric-immune-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis +[14] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Blood-derived +[4] 
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsMultiple MyelomaLymphoma, Mantle-Cell +[14] 
Global Approved IndicationsLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/08/30
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesUniversity Of PennsylvaniaLentigen Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Sao PauloNovartis Pharma AgNovartis Pharmaceuticals Corp +[5] 
Inactive CompaniesBeijing Sanwater Biological Technology Co LtdFujian Medical UniversityUniversity Of Cologne +[5] 
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[6] 
Inactive IndicationsHematologic NeoplasmsMultiple MyelomaLymphoma, Mantle-Cell +[8] 

Other Information

ATC CodeL01
Related LinksWikipediaDrugBankKEGG